- Conditions
- Candidemia, Candidiasis, Invasive
- Interventions
- Fosmanogepix, Caspofungin, Fluconazole, Placebo
- Drug
- Lead sponsor
- Basilea Pharmaceutica
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Location Directory
Clinical trials in Detroit, Michigan
This page shows live ClinicalTrials.gov search results for Detroit, Michigan, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7248
Shown on this page
12
Current sort
Recently updated
Location scope
Detroit, MI
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 481–492 of 7,248 matching trials in Detroit, MI.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Invasive Breast Carcinoma, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8
- Interventions
- Docetaxel, Lumpectomy, Mastectomy, Nab-paclitaxel, Paclitaxel, Pertuzumab, Radiation Therapy, Trastuzumab, Trastuzumab Emtansine
- Drug · Procedure · Biological + 1 more
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 2,175 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2038
- U.S. locations
- 999
- States / cities
- Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 674 more
- Conditions
- Breast Screening
- Interventions
- Digital Mammography, Digital Tomosynthesis Mammography, Laboratory Biomarker Analysis
- Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 45 Years to 74 Years · Female only
- Enrollment
- 108,508 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2029
- U.S. locations
- 133
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 107 more
- Conditions
- Alopecia Areata
- Interventions
- Upadacitinib, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 12 Years to 63 Years
- Enrollment
- 1,500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 78
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more
- Conditions
- Advanced Solid Tumors With KRAS G12C Mutations, Solid Tumor, Adult, Unresectable Solid Tumor, Metastatic Solid Tumor, Non Small Cell Lung Cancer, KRAS G12C
- Interventions
- FMC-376
- Drug
- Lead sponsor
- Frontier Medicines Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 293 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 15
- States / cities
- La Jolla, California • Orange, California • San Francisco, California + 11 more
- Conditions
- Ovarian Cancer
- Interventions
- Autologous genetically modified ADP-A2M4CD8 cells, Autologous genetically modified ADP-A2M4CD8 cells in combination with Nivolumab
- Genetic · Combination Product
- Lead sponsor
- USWM CT, LLC
- Industry
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 9
- States / cities
- Scottsdale, Arizona • Duarte, California • Augusta, Georgia + 6 more
- Conditions
- Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Oligometastatic Esophageal Adenocarcinoma, Oligometastatic Gastric Adenocarcinoma, Pathologic Stage IV Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IV Gastric Cancer AJCC v8, Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
- Interventions
- Capecitabine, Fluorouracil, Leucovorin, Leucovorin Calcium, Oxaliplatin, Radiation Therapy
- Drug · Radiation
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2028
- U.S. locations
- 453
- States / cities
- Anchorage, Alaska • Kingman, Arizona • Phoenix, Arizona + 276 more
- Conditions
- Hidradenitis Suppurativa (HS)
- Interventions
- SPY072, Placebo, bimekizumab
- Drug
- Lead sponsor
- Spyre Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 26
- States / cities
- Birmingham, Alabama • Rogers, Arkansas • Irvine, California + 20 more
- Conditions
- Mortality Prediction
- Interventions
- blood sample to check CXCL9 pre stem cell transplant and cell therapy
- Diagnostic Test
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Breast Cancer
- Interventions
- PF-07248144, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 215
- States / cities
- Anchorage, Alaska • Chandler, Arizona • Gilbert, Arizona + 150 more
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma
- Interventions
- Chemotherapy, Computed Tomography, Fludeoxyglucose F-18, Positron Emission Tomography, Surgical Procedure
- Drug · Procedure · Other
- Lead sponsor
- ECOG-ACRIN Cancer Research Group
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 235 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 81 more
- Conditions
- Metastatic Castration-resistant Prostate Cancer
- Interventions
- Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265]), Cabazitaxel, Abiraterone, Enzalutamide, Apalutamide, Darolutamide, Deutenzalutamide, Radium-223
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 670 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 28
- States / cities
- Dothan, Alabama • Phoenix, Arizona • Duarte, California + 24 more